Buy Medtronic (MDT) Weakness, Says Deutsche Bank

Go back to Buy Medtronic (MDT) Weakness, Says Deutsche Bank

Medtronic's (MDT) Weak Margins Spur PT Reduction - Leerink Partners

March 2, 2016 6:41 AM EST

Leerink Partners analyst, Danielle Antalffy, cut her PT on Medtronic (NYSE: MDT) as sales growth was offset by weaker margins. PT goes to $82 from $84 and Market Perform rating remains unchanged.

MDT shares traded lower yesterday driven by less positive operating leverage than expected, as... More

Needham & Company Cuts Price Target on Medtronic (MDT) as 3Q Revenue Misses Mark

March 1, 2016 11:50 AM EST

Needham & Company maintained a Buy rating on Medtronic, Inc. (NYSE: MDT), and cut the price target to $88.00 (from $91.00), following the company's 3Q earnings report. Revenue was reported at $6.934B vs. the consensus of $6.987B. Adjusted EPS was reported at $1.06, in-line with consensus estimates. MDT... More

Medtronic (MDT) Reports In-Line Q3 EPS

March 1, 2016 6:47 AM EST

Medtronic (NYSE: MDT) reported Q3 EPS of $1.06, in-line with the analyst estimate of $1.06. Revenue for the quarter came in at $6.93 billion versus the consensus estimate of $6.99 billion.

GUIDANCE:

Medtronic still sees FY16 EPS of $4.36 - $4.40, versus the consensus of $4.38.

For earnings history and earnings-related data on Medtronic (MDT) click here.

... More